Cardiovascular safety is great news, but the main problem with the Eisai drug is that it simply doesn’t work as monotherapy.
After falling short in a label-extension trial Johnson & Johnson still sees a path forward for its blood thinner in preventing venous thromboembolism.
Balloons are as good as stents, but it can be hard to get cardiologists to change their habits.
The Commander HF trial closes the door on a very sick heart failure population, leaving Johnson & Johnson and Bayer's label-expansion strategy looking shaky.
Off-label use of the mitral valve repair device, which accounts for a large chunk of its sales, could fall.
Pfizer eyes tafamidis approval in cardiac amyloidosis, but things could have been worse for its rivals, Alnylam and Ionis.
Johnson & Johnson and Bayer’s label-expansion strategy takes a hit, handing the advantage back to Bristol-Myers Squibb and Pfizer's Eliquis.
Featuring at the European Society of Cardiology meeting, which kicks off this weekend in Munich, are results with tafamidis, Xarelto and fish oil supplements.
In a quiet year for medical devices a couple of studies are still worth watching.